Veracyte Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests
PROCURE study will capture insights from 180 European breast cancer specialists, to develop consensus and recommendations
“As we’ve continued to learn more about how genomics impact treatment response and outcomes in breast cancer patients, genomic tests have become an invaluable tool for physicians,” said
The Delphi method is a survey technique and established methodology for facilitating consensus on complex issues. The process includes at least two rounds of a structured questionnaire containing items to which participants express their degree of agreement. Consensus is reached by grouping participants’ responses after each successive wave of questioning. The PROCURE study will be conducted by Adelphi Targis, a medical research, education and communication agency with extensive experience using the Delphi methodology, and guided by an independent scientific committee led by
Over approximately 12 months, the study will gather input from participants to:
- Comprehensively evaluate the existing evidence supporting the use of breast cancer genomic tests and the added value that clinicians attribute to them.
- Assess the current and optimized use of these tools in patients with differing clinical-pathological profiles.
- Establish recommendations on their use in routine clinical practice.
- Discuss future clinical applications and research opportunities to facilitate a precision medicine approach in breast cancer.
Applying the rigorous Delphi process, the PROCURE scientific committee will use published clinical evidence along with participants’ input to establish and publish consensus recommendations for the use of genomic tests in clinical practice.
“PROCURE will provide much-needed guidance to breast cancer clinicians and their patients, helping them fully access the benefits offered by genomic testing,” said
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the PROCURE study. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Factors that may impact these forward-looking statements can be found in Item 1A – “Risk Factors” in our Annual Report on Form 10-K filed with the
Investor and Media Contact: